Volume 1
Medical research and the NHS reforms / House of Lords, Select Committee on Science and Technology.
- Great Britain. Parliament. House of Lords. Science and Technology Committee.
- Date:
- 1995
Licence: Open Government Licence
Credit: Medical research and the NHS reforms / House of Lords, Select Committee on Science and Technology. Source: Wellcome Collection.
22/132 page 20
![nnn ee SEE EEEEEEE EE EIEEEEIS ESSE (iv) manage training schemes for health services researchers; (v) manage the Project Register; (vi) cultivate R&D networks; promote innovation, evaluation and implementation; “hold field [ie purchasers and providers] to account for use of R&D findings”. 1.41 Where RHAs have provided long-term funding for research centres or units, this will be taken over by the central R&D Directorate, “to ensure consistent standards of competition and quality...and co-ordination with support for units in the DH Centrally Commissioned Programme of research”. The arrangements whereby some CRDC programmes are commissioned and managed by RDRDs “will continue but will be reviewed in the light of the developing workloads and staffing arrangements in RDD and regional offices”. 1.42 When we met Professor Peckham in March, however, he indicated (Q1279) that more far-reaching changes to the organisation of the Strategy are planned for autumn 1995. In place of “Research for Health” and the Regional R&D Plans, a single annual plan will be produced covering NHS R&D activities run from London, Leeds and the regional offices. The distinction between national (CRDC) priorities and regional priorities will be abolished, leaving a single category of “important R&D”. The RDRDs will function as a team, sharing national responsibilities. Acknowledgements 1.43 We are grateful to all those who have given us evidence, whether face to face or in writing. We are especially grateful to the Vice-Chancellor and staff of the Queen’s University of Belfast, who received us hospitably on 14 February; to the Officers and Fellows of the Royal Society of Edinburgh (RSE), who opened their house to us on 28 February; and to Professor Samuel Thier, President of Massachusetts General Hospital and Professor of Medicine and’of Health Care Policy at Harvard Medical School, who took time during a visit to London in January to meet us and explain the US perspective on the issues before us. Finally, we acknowledge the invaluable assistance and cogent advice of our Specialist Adviser, Sir Keith Peters FRS, Regius Professor of Physic in the University of Cambridge. 1.44. The members of the Sub-Committee which prepared this report are listed in Appendix 1. Our witnesses are listed in Appendix 2. Their evidence is printed in two volumes, HL Paper 12-I (up to December 1994, ISBN 0 10 478495 4, HMSO £16.60) and HL Paper 12-II (since January 1995, ISBN 0 10 482395 X, HMSO £35.50 net).](https://iiif.wellcomecollection.org/image/b32219337_0001_0022.jp2/full/800%2C/0/default.jpg)
